Ram Waisbourd Net Worth

The estimated Net Worth of Ram Waisbourd is at least $375 Thousand dollars as of 1 February 2022. Mr. Waisbourd owns over 7,000 units of 89bio Inc stock worth over $56,770 and over the last 5 years he sold ETNB stock worth over $0. In addition, he makes $318,002 as Chief Operating Officer and Chief Business Officer at 89bio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Waisbourd ETNB stock SEC Form 4 insiders trading

Ram has made over 15 trades of the 89bio Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 7,000 units of ETNB stock worth $13,510 on 1 February 2022.

The largest trade he's ever made was exercising 7,000 units of 89bio Inc stock on 1 February 2022 worth over $13,510. On average, Ram trades about 5,833 units every 25 days since 2020. As of 1 February 2022 he still owns at least 7,000 units of 89bio Inc stock.

You can see the complete history of Mr. Waisbourd stock trades at the bottom of the page.

Ram Waisbourd biography

Ram Waisbourd serves as Chief Operating Officer and Chief Business Officer of the Company. Prior to joining our company, Mr. Waisbourd served as Vice President of Strategy and Transformation, Global Research and Development, at Teva Pharmaceutical Industries Ltd., a pharmaceutical company, from November 2016 to April 2018, where he was responsible for Teva research and development strategy, novel pipeline funding transactions and digital initiatives. Mr. Waisbourd also served as Vice President of Transformational Initiatives and Operations, Global Research and Development at Teva from September 2015 to October 2016 and Senior Director, Chief of the Research and Development Office from August 2012 to August 2015. Previously, Mr. Waisbourd served as Vice President of Business Development of XTL Biopharmaceuticals Ltd., a biotechnology company, and as Vice President of Biomedical Investments, an investment fund.

What is the salary of Ram Waisbourd?

As the Chief Operating Officer and Chief Business Officer of 89bio Inc, the total compensation of Ram Waisbourd at 89bio Inc is $318,002. There are 7 executives at 89bio Inc getting paid more, with Rohan Palekar having the highest compensation of $1,022,610.

How old is Ram Waisbourd?

Ram Waisbourd is 53, he's been the Chief Operating Officer and Chief Business Officer of 89bio Inc since 2018. There are 9 older and 6 younger executives at 89bio Inc. The oldest executive at 89bio Inc is Michael Hayden, 68, who is the Independent Director.

What's Ram Waisbourd's mailing address?

Ram's mailing address filed with the SEC is C/O 89BIO, INC., 142 SANSOME STREET, 2ND FLOOR, SAN FRANCISCO, CA, 94104.

Insiders trading at 89bio Inc

Over the last 5 years, insiders at 89bio Inc have traded over $17,267,666 worth of 89bio Inc stock and bought 14,519,952 units worth $208,678,684 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ..., and Advisors Llc Orbi Med Capit.... On average, 89bio Inc executives and independent directors trade stock every 28 days with the average trade being worth of $2,197,340. The most recent stock trade was executed by Rohan Palekar on 1 April 2024, trading 52,718 units of ETNB stock currently worth $575,153.

What does 89bio Inc do?

89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.

Complete history of Mr. Waisbourd stock trades at 89bio Inc

89bio Inc executives and stock owners

89bio Inc executives and other stock owners filed with the SEC include:

• Rohan Palekar,
  Chief Executive Officer, Director
• Rohan Palekar,
  CEO & Director
• Hank Mansbach,
  Chief Medical Officer
• Dr. Harry Mansbach M.D.,
  Chief Medical Officer
• Dr. Hank Mansbach M.D.,
  Chief Medical Officer
• Quoc Le-Nguyen,
  Chief Technical Operations Officer and Head of Quality
• Quoc Le-Nguyen,
  Chief Technical Operations Officer & Head of Quality
• Ram Waisbourd,
  Chief Operating Officer and Chief Business Officer
• Michael Hayden,
  Independent Director
• Anat Naschitz,
  Independent Director
• Gregory Grunberg,
  Independent Director
• Derek DiRocco,
  Independent Director
• Ryan Martins,
  Chief Financial Officer
• Steven Altschuler,
  Independent Chairman of the Board of Director
• Yun Bai,
  VP & Head of CMC
• Amanda Hill,
  VP of People & Culture
• Melissa Abel,
  VP of Commercial Strategy & Communication
• Shiva K. Natarajan,
  VP of Fin. & Principal Accounting Officer
• Ram Waisbourd,
  COO & Chief Bus. Officer
• Ryan Stephen Martins,
  Chief Financial Officer
• Charles Mc Wherter,
  
• Tomer Pontifax (Israel) V, ...,
  
• Capital Management, L.P.Ra ...,
  
• Advisors Llc Orbi Med Capit...,
  
• Capital Partners Iii, Llc L...,
  
• Kathleen Laporte,
  
• Edward Morrow Iii Atkinson,
  
• Capital Management, L.P.Ra ...,
  
• Harry H Mansbach,
  Chief Medical Officer
• Lota S. Zoth,
  
• Martin Babler,
  
• Francis Willard Sarena,
  Chief Operating Officer